{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:41:34Z","timestamp":1792644094598,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005329","name":"Guizhou Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119329","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:51:52Z","timestamp":1789253512000},"page":"119329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of quinoline-based derivatives as c-Met inhibitors for the treatment of non-small cell lung cancer"],"prefix":"10.1016","volume":"320","author":[{"given":"Zhongyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youli","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4709-9989","authenticated-orcid":false,"given":"Weike","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2026.119329_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119329_bib2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Incidence, update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2026.119329_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1309055","article-title":"Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119329_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119329_bib5","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-2600(24)00185-1","volume":"12","author":"Shiraishi","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119329_bib6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119329_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119329_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/A:1023768811842","article-title":"c-Met: structure, functions and potential for therapeutic inhibition","volume":"22","author":"Ma","year":"2003","journal-title":"Cancer Metastasis Rev."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119329_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","article-title":"Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy","volume":"18","author":"Comoglio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"28","key":"10.1016\/j.ejmech.2026.119329_bib10","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","article-title":"HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence","volume":"40","author":"Fu","year":"2021","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119329_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0092-8674(94)90318-2","article-title":"A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor\/scatter factor receptor family","volume":"77","author":"Ponzetto","year":"1994","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119329_bib12","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1021\/acs.jmedchem.3c00028","article-title":"Targeting MET: discovery of small molecule inhibitors as non-small cell lung cancer therapy","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119329_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210119","article-title":"Targeting MET in non-small cell lung cancer (NSCLC): a new old story?","volume":"24","author":"Spagnolo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119329_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"25","key":"10.1016\/j.ejmech.2026.119329_bib15","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119329_bib16","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"GEOMETRY mono-1 investigators, Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119329_bib17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119329_bib18","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-021-01584-0","article-title":"Savolitinib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119329_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s42003-025-07490-5","article-title":"Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer","volume":"8","author":"Lin","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2026.119329_bib20","first-page":"207","article-title":"Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor, recent results","volume":"201","author":"Gr\u00fcllich","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119329_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107512","article-title":"Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations","volume":"190","author":"Hong","year":"2024","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119329_bib22","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-12-3256","article-title":"Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition","volume":"73","author":"Katayama","year":"2013","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119329_bib23","doi-asserted-by":"crossref","first-page":"20666","DOI":"10.1074\/jbc.M110.213801","article-title":"Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197","volume":"286","author":"Eathiraj","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119329_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","article-title":"MET alterations in NSCLC\u2014Current perspectives and future challenges","volume":"18","author":"Remon","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.ejmech.2026.119329_bib25","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.3390\/ijms27135883","article-title":"Targeting MET in 2025: from exon 14 skipping to MET-amplified acquired resistance in non-small cell lung cancer","volume":"27","author":"Khan","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119329_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119329_bib27","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119329_bib28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ejmech.2014.09.095","article-title":"Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors","volume":"87","author":"Liao","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119329_bib29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ejmech.2014.06.068","article-title":"Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents","volume":"83","author":"Zhou","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119329_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ejmech.2016.07.059","article-title":"Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors","volume":"123","author":"Liu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119329_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126666","article-title":"Design, synthesis, and biological evaluation of 4-phenoxyquinoline derivatives as potent c-Met kinase inhibitor","volume":"29","author":"Yang","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119329_bib32","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1016\/j.bmc.2015.06.026","article-title":"Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors","volume":"23","author":"Liao","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119329_bib33","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119329_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112309","article-title":"Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3K\u03b1 inhibitors with potent antitumor activity","volume":"197","author":"Liao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119329_bib35","article-title":"Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)pyridine derivatives as novel FLT3-ITD inhibitors","volume":"289","author":"Wu","year":"2025","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:29:17Z","timestamp":1792643357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":35,"alternative-id":["S0223523426007749"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119329","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of quinoline-based derivatives as c-Met inhibitors for the treatment of non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119329"}}